Internship

Intern – National Roundtables & Coalitions

Posted on 4/7/2025

American Cancer Society

American Cancer Society

5,001-10,000 employees

Compensation Overview

$15/hr

+ Varies by geographic location + Experience + Skills + Specialty + Education

Washington, DC, USA

Candidates must be full-time students from all US geographies.

Category
Data Management
Data Analysis
Data & Analytics
Required Skills
Data Analysis
Requirements
  • Must be available for entirety of 8-week program: June 2 – July 25, 2025, at 37.5 hours per week.
  • Full-time student, if you are an undergraduate student, you have completed your freshman year of college.
  • Have a minimum of a B average (cumulative 3.0 on 4.0 scale);
  • Plan to continue your education in the following term/semester;
  • Upload a resume upon application submission.
Responsibilities
  • Support data collection, analysis and reporting across the business unit.
  • Coordinate and implement a mixed methods evaluation of the ECHO initiative.
  • Analyze online survey data and lead the development of the final evaluation report.
  • Support the National Roundtable evaluation plan by coordinating training and implementation of data collection instruments across the National Roundtables, including member surveys.
  • Support programmatic evaluation activities for the Roundtables and other NPI projects.
  • Cross-cutting activities may include manuscript / peer review presentation development, virtual ACS tour, and data visualization (infographic and/or dashboard development with existing data).
American Cancer Society

American Cancer Society

View

Company Size

5,001-10,000

Company Stage

Series B

Total Funding

$2.7M

Headquarters

Atlanta, Georgia

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine aligns with ACS's mission to enhance cancer care.
  • AI-driven drug discovery accelerates new cancer treatments, offering collaboration opportunities for ACS.
  • Telemedicine in cancer care increases access, supporting ACS's goal to improve patient access.

What critics are saying

  • Johnson & Johnson's TAR-200 monotherapy increases competition in bladder cancer treatment.
  • nference and BeiGene's collaboration may overshadow ACS-supported B-cell cancer research.
  • AstraZeneca's Imfinzi approval presents a competitive threat to ACS's influence in cancer treatment.

What makes American Cancer Society unique

  • American Cancer Society funds diverse cancer research, including colorectal, breast, and cervical cancers.
  • ACS hosts impactful events like Relay For Life to engage communities in cancer awareness.
  • ACS collaborates with partners like Pizza Ranch and Isabel Bloom for fundraising initiatives.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Paid Vacation

401(k) Retirement Plan

Wellness Program

Professional Development Budget

Company News

PR Newswire
Apr 21st, 2025
Johnson Johnson Unveils Highly Anticipated And Potential Practice-Changing Data In Bladder Cancer Treatment At Aua

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancerRARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology plenary session on Saturday, April 26.Bladder cancer ranks among the top ten most common cancers worldwide, affecting nearly a million people each year.1 Despite advancements, standard treatment has remained largely unchanged for over 40 years, leaving patients with limited treatment options if initial BCG therapy does not work.2 TAR-200 delivers sustained medication directly into the bladder and, in a pre-clinical setting, has been shown to allow for depth of penetration across bladder tissue layers.3"Patients with bladder cancer need more effective treatment options that are both tolerable and easily incorporated into everyday practice, especially for those with HR-NMIBC, a highly recurrent disease that often necessitates difficult, life-altering decisions like bladder removal," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. "TAR-200 provides a new approach, with clinical data showing an impressive complete response rate, meaning the cancer was undetectable following treatment. The highly anticipated 12-month duration of response findings from our Cohort 2, SunRISe-1 study further support the potential for patients to remain cancer-free for a clinically meaningful period."A second plenary presentation will feature first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 monotherapy in patients with BCG–unresponsive, papillary-only HR-NMIBC. In this patient population, bladder removal remains a standard treatment, but many patients are elderly, have significant comorbidities, or are unwilling to undergo radical surgery, making treatment challenging.4"Patients deserve more than the currently available treatment options

PR Newswire
Apr 17th, 2025
Nference And Beigene Collaborate To Drive New B-Cell Cancer Research

Real-world data study aims to improve treatment options for chronic lymphocytic leukemia and small lymphocytic lymphoma patientsCAMBRIDGE, Mass., April 17, 2025 /PRNewswire/ -- nference, a company dedicated to transforming healthcare by making biomedical data computable, today announced a collaboration with BeiGene, Ltd, a global oncology company that intends to change its name to BeOne Medicines Ltd., to unlock new insights in treating B-cell cancers. The collaboration will leverage nference's proprietary Agentic AI platform to deepen understanding of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) treatment patterns. B-cell cancers, including CLL and SLL, are a group of malignancies affecting lymphocytes, a type of white blood cell crucial to immune function. These cancers impact thousands, with CLL being the most common adult leukemia in the U.S. This retrospective descriptive analysis will review more than 700 patient charts to identify real-world treatment patterns

MSU Today
Apr 14th, 2025
American Cancer Society grant fuels MSU research in colorectal, breast and cervical cancer

Four dedicated researchers from Michigan State University have received grants totaling more than $3 million from the American Cancer Society, or ACS, to find new ways to prevent, detect, treat and help patients survive colorectal, breast and cervical cancer.

Greater Utica Chamber of Commerce
Apr 9th, 2025
Relay For Life of Central NY presented by Upstate Cancer Center Set for June 14th

The American Cancer Society's annual Relay For Life event is happening on Saturday, June 14th from Noon - 10 PM at Delta Lake State Park in Rome.

Pizza Ranch
Apr 9th, 2025
Wednesday Story of Impact - American Cancer Society

Pizza Ranch is a proud partner with the American Cancer Society.

INACTIVE